

## Mirvaso® (brimonidine) – First-time generic

- On January 4, 2023, Padagis Israel launched an <u>AB-rated</u> generic version of Galderma's <u>Mirvaso</u> (brimonidine) gel.
- Mirvaso is approved for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.